PGA-timolol combo effective for POAG

Article

A combination of prostaglandin analog (PGA) and timolol 0.1 & gel reduces both IOP and fluctuations in primary-angle glaucoma patients, states a recent paper in European Journal of Ophthalmology.

A combination of prostaglandin analog (PGA) and timolol 0.1 & gel reduces both IOP and fluctuations in primary-angle glaucoma patients, states a recent paper in European Journal of Ophthalmology.

Dr Carlo Nucci et al., Ophthalmology Unit, Department of Exp. Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, administered fixed combinations of PGA-timolol in 64 eyes of 32 patients. This included 17 patients receiving a latanoprost-timolol fixed combination, 9 patients receiving a travoprost-timolol fixed combination and six who were administered bimatoprost-timolol fixed combination. The primary endpoint was the comparison between efficacy of fixed and unfixed combinations in lowering IOP and short-term IOP fluctuations.

All unfixed treatment combinations induced an IOP reduction that was significantly higher than the corresponding fixed treatment combinations. IOP diurnal fluctuations significantly decreased after unfixed combinations were administered, as well as increasing the percentage of patients with daily IOP fluctuation of 2 mm or less.

PGA and timolol was the most effective POAG treatment when administered as an unfixed combination. Once saily timolol 0.1% gel is a valuable treatment option as it reduces both IOP and daily fluctuations.

To read the journal abstract please click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.